Search


How a new CEO has been trying to position Editas to execute on the promise of CRISPR
Gilmore O’Neill is working to inject stability and focus at Editas as it aims to execute on both ex-vivo and in-vivo crispr gene therapies.
Aug 2, 2023
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
​
​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.